Ukwelashwa okusha kokuqala okuqondiswe kumetabolism yomdlavuza

A BAMBA MahhalaRelease 4 | eTurboNews | eTN
Isithombe sikaLinda Hohnholz
Ibhalwe ngu Linda Hohnholz

UServier namuhla umemezele ukuthi i-US Food and Drug Administration (FDA) yamukele i-supplementary New Drug Application (sNDA) yenkampani ye-TIBSOVO® (amaphilisi e-ivosidenib) njengendlela yokwelapha engaba khona ezigulini ezine-IDH1-mutated acute myeloid leukemia (AML) engazange iphathwe ngaphambilini. I-sNDA inikezwe i-Priority Review, esheshisa ukubuyekezwa futhi ifinyeze umgomo wesikhathi sokubuyekeza ukusuka ezinyangeni eziyi-10 kuye kwezingu-6. Ukubuyekezwa Okubalulekile ngokuvamile kunikezwa emithini enganikeza intuthuko enkulu ekwelashweni noma engase inikeze ukwelashwa lapho kungekho ukwelashwa okwanele okukhona.             

"Ezithendeni zokugunyazwa kwethu kwakamuva kwe-FDA kwe-TIBSOVO ku-cholangiocarcinoma, sijabule ngalesi sinyathelo esibalulekile sokuqhubekela phambili ekucabangeni kwe-ejensi yokwandisa inkomba yayo yamanje ukuze ihlanganise nokwelashwa kweziguli ezine-IDH1-mutated acute myeloid leukemia ngaphambili," kusho uDavid. K. Lee, Isikhulu Esiphethe, i-Servier Pharmaceuticals. “Sijabule ngomfutho omuhle walolu hlelo njengoba siqhubeka nokukhulisa ubuholi bethu ku-oncology futhi silethe eminye imithi eshintsha impilo ezigulini ezinomdlavuza okunzima ukuwelapha.”

Ukwamukelwa kwe-sNDA kusekelwa imiphumela yocwaningo lwe-AGILE, uhlolo lomhlaba wonke, lweSigaba sesi-3 ezigulini ezine-AML eguquliwe ye-IDH1 engazange iphathwe ngaphambilini, eyethulwa ku-2021 American Society of Hematology Annual Meeting and Exposition. Idatha yabonisa ukuthi ukwelashwa nge-TIBSOVO kuhlanganiswe ne-azacitidine kuthuthukisa kakhulu ukusinda ngaphandle kwemicimbi (EFS) (isilinganiso sengozi [HR] = 0.33, 95% CI 0.16, 0.69, 1-sided P = 0.0011 1,2). Ukwengeza, inhlanganisela ye-TIBSOVO ne-azacitidine ibonise ukuthuthukiswa okuphawulekayo kwezibalo ekusindeni okuphelele (OS) (HR = 0.44 [95% CI 0.27, 0.73]; 1-sided P = 0.0005), ene-OS ephakathi yezinyanga ezingu-24.0.

"I-TIBSOVO iyindlela yokwelapha yokuqala eqondiswe ku-metabolism yomdlavuza ukukhombisa ukusinda okuthuthukisiwe kwemicimbi kanye nokusinda okuphelele ngokuhambisana ne-azacitidine ezigulini ezine-AML eguqulwe i-IDH1 engazange iphathwe ngaphambili," kusho uSusan Pandya, MD, iPhini Likamongameli Wezokuthuthukiswa Komtholampilo kanye neNhloko yeCancer Metabolism Global. I-Development Oncology & Immuno-Oncology, I-Servier Pharmaceuticals. "Ngalokhu kwamukelwa kwe-FDA Yokubuyekezwa Okubalulekile, siseduze nokunikeza le nketho yokwelashwa ebalulekile ezigulini zase-US futhi sibheke ngabomvu ukusebenzelana nezinhlaka ezilawulayo emhlabeni jikelele."

I-TIBSOVO[*] okwamanje ivunyelwe e-US njenge-monotherapy ekwelapheni abantu abadala abane-IDH1-mutant relapsed noma i-refractory acute myeloid leukemia (AML), nakubantu abadala abane-IDH1-mutant AML esanda kutholwa abaneminyaka engu-≥75 ubudala noma abanesifo se-IDH1-mutant AML. izifo ezithathelwanayo ezivimbela ukusetshenziswa kwe-intensive induction chemotherapy. Muva nje, i-TIBSOVO iye yagunyazwa njengokwelashwa kokuqala futhi okuhlosiwe kuphela ezigulini ezine-cholangiocarcinoma eguquliwe ye-IDHXNUMX eyalashwa ngaphambilini.

Emzamweni wokuletha izindlela zokwelapha ezintsha ezigulini eziphila nomdlavuza okunzima ukuwelapha, u-Servier wenze i-oncology yaba yinto ehamba phambili emhlabeni wonke, futhi yabela ngaphezu kwama-50% esabelomali sayo socwaningo nentuthuko ocwaningweni lomdlavuza. Njengoba kunezimpahla ezingaphezu kuka-21 ze-oncology ezigabeni ezihlukene zokuthuthuka komtholampilo, kanye namaphrojekthi ocwaningo angama-20 aqhubekayo, u-Servier uzibophezele ekutholeni izisombululo ezibhekana nezidingo zesiguli kulo lonke uhlobo lwezifo kanye nezinhlobo ezahlukahlukene zesimila.

Mayelana umbhali

Isithombe sikaLinda Hohnholz

Linda Hohnholz

Umhleli omkhulu we eTurboNews ezinze eTN HQ.

Bhalisa
Yazisa ngakho
isivakashi
0 Amazwana
Okungaphakathi Okuphakelayo
Buka wonke amazwana
0
Ungathanda imibono yakho, ngicela uphawule.x
Yabelana ku...